Article
Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA.
PloS one - 1 Jan 2020
Sasaki Noriyuki, Iwaya Takeshi, Chiba Takehiro, Fujita Masashi, Ju Zhenlin, Endo Fumitaka, Yaegashi Mizunori, Hachiya Tsuyoshi, Sugimoto Ryo, Sugai Tamotsu, Siwak Doris R, Liotta Lance A, Lu Yiling, Mills Gordon B, Nakagawa Hidewaki, Nishizuka Satoshi S
Abstract excerpt
Circulating tumor DNA (ctDNA) is released from tumor cells into blood in advanced cancer patients. Although gene mutations in individual tumors can be diverse and heterogenous, ctDNA has the potential to provide comprehensive biomarker information. Here, we performed multi-region sampling (three sites) per resected specimen from 10 gastric cancer patients followed by targeted sequencing and proteomic profiling...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.